Literature DB >> 24239060

Novel TPM3 mutation in a family with cap myopathy and review of the literature.

T Schreckenbach1, J M Schröder2, T Voit3, A Abicht4, E Neuen-Jacob5, A Roos6, S Bulst4, C Kuhl7, J B Schulz8, J Weis6, K G Claeys9.   

Abstract

Cap myopathy is a rare congenital myopathy characterized by the presence of caps within muscle fibres and caused by mutations in ACTA1, TPM2 or TPM3. Thus far, only three cases with TPM3-related cap myopathy have been described. Here, we report on the first autosomal dominant family with cap myopathy in three-generations, caused by a novel heterozygous mutation in the alpha-tropomyosin-slow-encoding gene (TPM3; exon 4; c.445C>A; p.Leu149Ile). The three patients experienced first symptoms of muscle weakness in childhood and followed a slowly progressive course. They presented generalized hypotrophy and mild muscle weakness, elongated face, high arched palate, micrognathia, scoliosis and respiratory involvement. Intrafamilial variability of skeletal deformities, respiratory involvement and mild cardiac abnormalities was noted. Muscle MRI revealed a recognizable pattern of fatty muscle infiltration and masseter muscle hypertrophy. Subsarcolemmal caps were present in 6-10% of the fibres and immunoreactive with anti-tropomyosin antibodies. We conclude that the MRI-pattern of muscle involvement and the presence of masseter muscle hypertrophy in cap myopathy may guide molecular genetic diagnosis towards a mutation in TPM3. Regular respiratory examinations are important, even if patients have no anamnestic clues. We compare our findings to all cases of cap myopathy with identified mutations (n=11), thus far reported in the literature.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha tropomyosin slow; Caps; Congenital myopathy; Genotype–phenotype correlations; Muscle fibre inclusions; Whole-body muscle MRI

Mesh:

Substances:

Year:  2013        PMID: 24239060     DOI: 10.1016/j.nmd.2013.10.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  4 in total

Review 1.  Update on Congenital Myopathies in Adulthood.

Authors:  George Konstantinos Papadimas; Sophia Xirou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

2.  Nemaline Myopathy in Brazilian Patients: Molecular and Clinical Characterization.

Authors:  Juliana Gurgel-Giannetti; Lucas Santos Souza; Guilherme L Yamamoto; Marina Belisario; Monize Lazar; Wilson Campos; Rita de Cassia M Pavanello; Mayana Zatz; Umbertina Reed; Edmar Zanoteli; Acary Bulle Oliveira; Vilma-Lotta Lehtokari; Erasmo B Casella; Marcela C Machado-Costa; Carina Wallgren-Pettersson; Nigel G Laing; Vincenzo Nigro; Mariz Vainzof
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

3.  Muscle weakness in TPM3-myopathy is due to reduced Ca2+-sensitivity and impaired acto-myosin cross-bridge cycling in slow fibres.

Authors:  Michaela Yuen; Sandra T Cooper; Steve B Marston; Kristen J Nowak; Elyshia McNamara; Nancy Mokbel; Biljana Ilkovski; Gianina Ravenscroft; John Rendu; Josine M de Winter; Lars Klinge; Alan H Beggs; Kathryn N North; Coen A C Ottenheijm; Nigel F Clarke
Journal:  Hum Mol Genet       Date:  2015-08-24       Impact factor: 6.150

4.  TPM3 deletions cause a hypercontractile congenital muscle stiffness phenotype.

Authors:  M Papadaki; J M de Winter; M B Neu; S Donkervoort; J Kirschner; V Bolduc; M L Yang; M A Gibbons; Y Hu; J Dastgir; M E Leach; A Rutkowski; A R Foley; M Krüger; E P Wartchow; E McNamara; R Ong; K J Nowak; N G Laing; N F Clarke; Cac Ottenheijm; S B Marston; C G Bönnemann
Journal:  Ann Neurol       Date:  2015-11-13       Impact factor: 10.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.